Rahul Jasuja's questions to XBiotech (XBIT) leadership • Q3 2016
Question
Rahul Jasuja of Noble Finance inquired about the expected timeline for the CHMP decision on Xilonix, the status of the European colorectal cancer data publication, enrollment progress for the global Phase III trial, and future plans for non-small cell lung cancer trials, particularly with anti-PD-1 inhibitors.
Answer
Founder, President & CEO John Simard stated that the EMA interactions are following a standard course, with a decision possible by mid-December or as late as mid-February. He confirmed the European Phase III study publication is in progress. Medical Director Mike Stecher added that the global colorectal cancer study is on track for an interim analysis in Q1 2017. Regarding non-small cell lung cancer, Mr. Simard noted that while the NCIC collaboration ended, the company is still exploring combinations with EGFR inhibitors and is evaluating opportunities to combine Xilonix with PD-1 inhibitors due to significant investigator interest.